Our investigators collaborate to answer fundamental questions in cancer biology and to address unmet clinical needs by conducting translational studies. They partner with our dedicated core facilities, which provide state-of-the art technologies and expertise necessary to effectively to pursue modern cancer research.
These efforts involve many specialists, from immunologists to cell biologists and experts in epigenetics, metabolism, the microbiome and aging. As one of seven official basic research cancer centers designated by the National Cancer Institute—the highest federal rating a basic research cancer center can achieve—we help advance the field by leveraging the capabilities of the Conrad Prebys Center for Chemical Genomics, which offers unparalleled technical expertise in drug discovery.
We are committed to performing impactful translational multi-disciplinary research relevant to the diagnosis and treatment of cancer.
Director’s Statement
“We are committed to performing impactful translational multi-disciplinary research relevant to the diagnosis and treatment of cancer.”
Cosimo Commisso, PhDInterim Center Director, Deputy Director
By better understanding how cell nuclei give rise to tumors and other malignancies, we learn how to prevent, block and repair genetic growth modifications that lead to cancer.
Cancer is the consequence of highly organized cells and molecules, fueled by disinformation, that create abnormal tissues and deadly tumors. We seek to understand how cancer cells survive and thrive within their microenvironment, and how to intervene to combat them.
Using the most sophisticated technologies, we are advancing the discovery and development of new cancer drugs based on emerging insights into cancer biology at the molecular level.
The nine shared resources of the cancer center feature specialized services that sustain and promote research by both faculty members and other nonprofit and for-profit investigators in cancer research.
Feb 17, 2025
Feb 12, 2025
Feb 10, 2025
Feb 6, 2025
Feb 3, 2025
Feb 3, 2025